MARKET WIREReuters • 1h ago
Iranians have left Doha talks, draft proposal for US deal being circulated, official says - ReutersIranians have left Doha talks, draft proposal for US deal being circulated, official says Reuters
Why TARA Stock slipped -1.59% Today — RQD Quant Desk Flash
$2.48 -1.59% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.47
Protara Therapeutics Inc. (TARA) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • SELL / AVOID
Cap $148.9M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on TARA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is TARA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Protara Therapeutics Inc. (NASDAQ: TARA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $2.48 (-1.59% 1D, market cap $148.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, TARA ranks #461 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does TARA compare to STRO and CRDL in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), TARA carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -34.7%. By comparison, STRO (Sutro Biopharma Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $151.6M) and CRDL (Cardiol Therapeutics Inc. (Class A)) posts a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $141.2M). Among the 5-stock peer group, TARA leads on earnings multiple (N/A) while CMPX leads on capital efficiency (-34.6% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for TARA?
▼
Per TARA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001359931), Protara Therapeutics Inc. generated $0 in revenue, -$57.4M in net income, and -$56.5M in free cash flow against $209.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.47 (-0.48%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-6.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TARA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (43/100 Composite)
🔍 WHY TARA SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (30% of score)
FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 38.3 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (23% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$2.76-15.9% Next Q
51
Q2 (-2Q)Grade D$2.32+0.4% Next Q
48
Q3 (-1Q)Grade D$2.33+6.4% Next Q
46
CurrentGrade D-$2.48-6.7% Hist 90D α
43
Trajectory: C- (51) → D- (43)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a TARA Turnaround Squeeze
While TARA currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.19) and Max Pain ($2.60) forces dealer call-delta covering toward $8.21.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $TARA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TARA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why TARA Stock slipped -1.59% Today — RQD Quant Desk Flash
Protara Therapeutics Inc. (TARA) slipped -1.59% to $2.48, trading at 4% of its 52-week range ($2.28 – $7.82). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 4% of its 52-week range ($2.28 – $7.82) with RSI-14 at 38.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.48 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live TARA Headlines & Catalysts
MARKET WIREReuters • 1h ago
China's foreign minister pushes for dialogue to resolve Middle East conflict - ReutersChina's foreign minister pushes for dialogue to resolve Middle East conflict Reuters
MARKET WIREReuters • 3h ago
COMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag - ReutersCOMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag Reuters
MARKET WIREReuters • 4h ago
Saudi civil defence sounds all-clear after alerts in southern cities - ReutersSaudi civil defence sounds all-clear after alerts in southern cities Reuters
MARKET WIREReuters • 5h ago
World's energy supply buffers have been eroded, ADNOC CEO says - ReutersWorld's energy supply buffers have been eroded, ADNOC CEO says Reuters
MARKET WIREReuters • 6h ago
Gold rebounds from one-year low as oil slides ahead of US midterms - ReutersGold rebounds from one-year low as oil slides ahead of US midterms Reuters
MARKET WIREReuters • 7h ago
China's Xi says Middle East should not become battleground for great power rivalry - ReutersChina's Xi says Middle East should not become battleground for great power rivalry Reuters
MARKET WIREReuters • 9h ago
Reliance earnings, lower oil prices power India's Sensex to near two-month high - ReutersReliance earnings, lower oil prices power India's Sensex to near two-month high Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TARA)
- ✓Walkthrough of TARA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
TARA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -53.47%🛡️ HOLDING TREND SUPPORT
2026-10-30O $2.51H $2.57L $2.43C $2.48VOL 580.9K
RES: $3.67SUP: $2.21SMA50: $3.19SMA200: $4.56
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
TARA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on TARA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for TARA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TARA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TARA)
Health Care Rank #461 of 1016
⚔️ STRO vs TARA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (TARA vs. STRO, CRDL, CHRS, CMPX)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Protara Therapeutics Inc. (TARA) ranks #461 by composite RQD confidence (43/100, grade D-) and #611 by equity capitalization ($148.9M). Within this direct 5-issuer industry benchmark cohort, TARA leads on earnings valuation at N/A trailing P/E, while CMPX leads on capital efficiency and profitability with -34.6% ROIC and — gross margin. CRDL currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with TARA at 43/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TARA
ACTIVE
Protara Therapeutics Inc. | D- | 43/100 | — | — | -34.7% | -1.59% | $148.9M | Benchmark Subject |
| STRO Sutro Biopharma Inc. | D- | 36/100 | — | — | -35.0% | -0.44% | $151.6M | /stro-vs-tara → |
| CRDL Cardiol Therapeutics Inc. (Class A) | D+ | 52/100 | — | — | — | -5.13% | $141.2M | /crdl-vs-tara → |
| CHRS Coherus Oncology Inc. | D- | 36/100 | — | — | -35.0% | -7.60% | $138.8M | /chrs-vs-tara → |
| CMPX Compass Therapeutics Inc. | D | 46/100 | — | — | -34.6% | +4.01% | $136.2M | /cmpx-vs-tara → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001359931In its most recent audited fiscal period (FY2025, filed 2025-12-31), Protara Therapeutics Inc. (TARA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$57.4M, operating cash flow of -$56.4M, and free cash flow of -$56.5M (-57.4% YoY). On the balance sheet, TARA closed FY2025 with $209.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$57.4M | -$56.4M | -$56.5M | $209.5M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$44.6M | -$35.8M | -$35.9M | $181.5M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$40.4M | -$37.6M | -$37.6M | — | — |
3. TARA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs TARA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Protara Therapeutics Inc. (NASDAQ: TARA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $2.48 (-1.59% 1D, market cap $148.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, TARA ranks #461 in composite RQD confidence.
How does TARA compare to STRO and CRDL in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), TARA carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -34.7%. By comparison, STRO (Sutro Biopharma Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $151.6M) and CRDL (Cardiol Therapeutics Inc. (Class A)) posts a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $141.2M). Among the 5-stock peer group, TARA leads on earnings multiple (N/A) while CMPX leads on capital efficiency (-34.6% ROIC).
What are the biggest fundamental strengths and SEC risk factors for TARA?
Per TARA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001359931), Protara Therapeutics Inc. generated $0 in revenue, -$57.4M in net income, and -$56.5M in free cash flow against $209.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is TARA trading relative to its 50-day, 200-day, and 52-week technical levels?
TARA last traded at $2.48 (-1.59% on volume of 581,167 shares), positioning the stock -22.26% below its 50-day simple moving average ($3.19) and -45.61% below its 200-day simple moving average ($4.56). Across its 52-week range of $2.28 to $7.82, TARA sits at the 3.6% percentile with a 14-day RSI of 38.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.17 to $2.79).
TARA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is TARA stock moving today?
Why TARA Stock slipped -1.59% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.